Issue: April 2004
April 01, 2004
1 min read

Levofloxacin 1.5% approved

Issue: April 2004
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

OSAKA, Japan — U.S. regulators have approved levofloxacin ophthalmic solution 1.5% (Iquix, Santen) for the treatment of both gram-positive and gram-negative bacterial corneal ulcers, said the manufacturer.

The approval was based on data from two randomized, double-masked multicenter trials of 280 patients with positive cultures.

In these trials, Iquix achieved clinical cure rates ranging between 73% and 87%, according to Santen. The most frequently reported adverse events were headache and a taste disturbance following instillation, which occurred in 8% to 10% of the study participants. The company said it expects to launch the drug later this year.